Egalet Announces Issuance of U.S. Patent Covering Guardian™ Technology and Its Abuse-Deterrent Product Candidates

Nov 12, 2015, 06:00 ET from Egalet

WAYNE, Pa., Nov. 12, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the issuance of a patent by the U.S. Patent and Trademark Office (USPTO) covering products employing Egalet's Guardian Technology. U.S. patent number U.S. 9,168,228 titled "Pharmaceutical Compositions Resistant to Abuse" was issued October 27, 2015.

"This patent expands our intellectual property portfolio protecting products using our proprietary abuse-deterrent Guardian Technology," said Bob Radie, president and chief executive officer of Egalet. "We will continue to strengthen our patent position covering our products which in some cases extends to 2033 to support our organic growth."

Egalet currently has been granted 14 U.S. patents and 69 patents outside of the United States that cover Guardian Technology and its product candidates.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. The Company has two approved products: OXAYDO™ (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using Egalet's proprietary Guardian™ Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO, formerly known as Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Full additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, please visit sprix.com and for Oxaydo please visit oxaydo.com. For full prescribing information on SPRIX, including the black box warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.

Safe Harbor
Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet's clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet's ability to obtain regulatory approval of Egalet's product candidates; ability to maintain the intellectual property position of Egalet's products and product candidates; ability to have third parties manufacture Egalet's products; the Company's ability to service its debt obligations; competitive factors; the Company's ability to find and hire qualified sales professionals; the receptivity in the marketplace and among physicians to Egalet's products; general market conditions; and other risks factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275

SOURCE Egalet



RELATED LINKS

http://egalet.com